Taken together, ablation of CCR2-MCP1 signaling boosts anti-tumor efficacy by preventing the tumor infiltration of immunosuppressive CCR2+ M2 MDSCs and by promoting cytotoxic T cell responses. This evidence concerns the gene CCL2 and neoplasm.